talazoparib

TALAZOPARIB (TAL a ZOE pa rib) is a type of chemotherapy medication that works by targeting certain enzymes in cancer cells to inhibit their growth. It is primarily prescribed for the treatment of breast cancer, but may also have other uses. If you have any questions about this medication, consult your healthcare provider or pharmacist.

Talzenna, a brand name for the drug Talazoparib, is an oral PARP inhibitor developed by Pfizer. It is specifically used for treating advanced breast cancer in patients with germline BRCA mutations.

Talazoparib functions as a PARP inhibitor, which hinders the activity of PARP, a protein responsible for DNA repair. By obstructing PARP, the drug prevents cancer cells from repairing their damaged DNA, ultimately leading to their demise. PARP inhibitors are classified as targeted therapy.

No, Tukysa does not have a known side effect of causing hair loss. Hair loss was not reported in the clinical trials of Tukysa. It is important to note that Tukysa is typically used in combination with the chemotherapy drug Xeloda (capecitabine) for the treatment of breast cancer.

Herzuma is a medication prescribed for adults with HER2+ breast cancer. It is not a form of chemotherapy, but it may be used in conjunction with chemotherapy. Herzuma is classified as an antibody therapy.

According to the study, hair loss was not a frequent occurrence in either of the two treatment groups. Only 4.7% of individuals who received TUKYSA in addition to trastuzumab and capecitabine experienced hair loss, compared to 3.6% of those who were treated with trastuzumab and capecitabine alone.

Talazoparib works by inhibiting the PARP1/2 enzymes, which are crucial for detecting and repairing single-strand DNA damage. This leads to PARP trapping, where the PARP proteins are unable to detach from the inhibitor and DNA, preventing the repair, replication, and transcription of DNA. Ultimately, this can lead to cell death in cancer cells.

Talazoparib (Talzenna, Pfizer, Inc.) in combination with enzalutamide has been approved by the US Food and Drug Administration (FDA) on 20 June 2023 for the treatment of homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC). Full prescribing information for Talzenna can be found here.

Agarwal discussed the sequencing of enzalutamide (Xtandi) plus talazoparib (Talzenna) in his clinic for the treatment of homologous recombination repair (HRR)-mutated metastatic castration-resistant prostate cancer (CRPC), following the FDA approval in June 2023.

On December 1, 2023, Eli Lilly and Company’s drug, Jaypirca (pirtobrutinib), received accelerated approval from the Food and Drug Administration. This approval is specifically for adults diagnosed with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have undergone at least two previous lines of treatment, including both a BTK inhibitor and a BCL-2 inhibitor.

The Exablate Prostate, created by Insightec, is a healthcare technology that utilizes ultrasound to specifically target and eliminate cancer cells in the prostate, without causing harm to nearby healthy tissues.

The US Food and Drug Administration (FDA) has approved the supplemental New Drug Application for Xtandi (enzalutamide), a small-molecule drug developed by Astellas Pharma Inc. and Pfizer Inc., for the treatment of previously treated patients with prostate cancer.

Radiation therapy is a highly effective treatment option for cancer, utilizing high levels of radiation energy to combat the disease. This form of therapy is particularly beneficial for individuals with early-stage prostate cancer, as well as older men or those with preexisting health conditions.

Docetaxel (Taxotere) is the primary chemotherapy drug used for treating prostate cancer, often administered alongside prednisone, a steroid medication. Many men report experiencing relief from disease-related symptoms such as pain, fatigue, and loss of energy after beginning treatment with docetaxel.

Sipuleucel-T (Provenge) is not a traditional vaccine, but rather a cancer vaccine that works by boosting the immune system to target and attack prostate cancer cells, rather than preventing infections.

Pluvicto is a form of targeted radioligand therapy that utilizes radioactive atoms to specifically target and deliver radiation to cancer cells, effectively fighting the disease while minimizing harm to healthy tissues. While there is currently no cure for advanced stage cancer, Pluvicto has the potential to extend the lives of those affected by the disease.

Common side effects of this medication may include fatigue, nausea, vomiting, diarrhea, loss of appetite, headache, hair loss, anemia, low white blood cell count, and low platelet count.

TALZENNA® is an effective treatment for locally advanced or metastatic gBRCA-mutated, HER2- breast cancer. It offers a convenient once-daily oral dose, making it a viable alternative to chemotherapy.

Among the 18 patients with advanced breast cancer and a germline BRCA1/2 mutation, talazoparib monotherapy at a daily dose of 1 mg showed a 50% response rate and an 86% clinical benefit rate after 24 weeks in a phase 1 trial.

Talzenna (talazoparib) belongs to the PARP inhibitors drug class and is frequently prescribed for the treatment of Breast Cancer and Prostate Cancer. The price of Talzenna oral capsule 0.1 mg is approximately $18,452 for a 30-capsule supply, which may vary depending on the pharmacy you choose.

Talazoparib belongs to a group of drugs known as poly (ADP-ribose) polymerase (PARP) inhibitors. Its mechanism of action involves inhibiting the growth of cancer cells, either by stopping their growth or slowing it down.

Talazoparib (TALZENNA, Pfizer Inc.), a PARP inhibitor, was approved by the FDA on October 16, 2018. This approval is for patients with locally advanced or metastatic breast cancer who have deleterious or suspected deleterious gBRCAm and are HER2-negative.

The typical adverse reactions experienced by breast cancer patients undergoing treatment with HERZUMA include headache, diarrhea, nausea, chills, fever, infection, cardiac muscle weakness, insomnia, cough, and rash.

Talzenna, a brand name for the drug Talazoparib, is an oral PARP inhibitor developed by Pfizer. It is specifically used for treating advanced breast cancer in patients with germline BRCA mutations.

Common side effects of chemotherapy include fatigue, nausea, hair loss, infections, anemia, bruising and bleeding, sore mouth, and loss of appetite.

Possible side effects include an elevated susceptibility to infections, difficulties with blood clotting leading to excessive bleeding, fatigue, and shortness of breath due to a decrease in red blood cell count. Other potential side effects may include nausea or vomiting, fatigue, diarrhea, indigestion, changes in taste, headaches, and dizziness.

Talazoparib effectively inhibits poly(ADP-ribose) polymerase (PARP) in patients with impaired DNA damage response mechanisms, leading to notable efficacy.

Talzenna, a drug developed by Pfizer, Inc., was approved by the Food and Drug Administration on June 20, 2023.

Oxaliplatin’s neurotoxic effects may have dosage restrictions. Oxaliplatin use results in peripheral neuropathy in 85-95% of patients, leading to pain, functional limitations, and loss of tendon reflexes. Additionally, pulmonary fibrosis has been observed in patients undergoing oxaliplatin therapy.

Talazoparib, the most potent PARPi approved by the FDA, exhibits more extensive interactions with the active sites of PARP1 compared to olaparib. This suggests that talazoparib has a greater affinity for PARP1.

Talazoparib (BMN 673) is a PARP inhibitor that has been found to have a significantly stronger antitumor effect in in-vitro studies on HRR-deficient cells (cells with BRCA1, BRCA2, PTEN gene defects) compared to other PARP inhibitors such as olaparib, rucaparib, and veliparib. The assumed strength of Talazoparib’s action is 20 to 200 times greater than these other inhibitors.

Based on current evidence, there is no significant difference in effectiveness between olaparib, niraparib, and rucaparib. However, olaparib may have fewer severe adverse events compared to the other two.

Talzenna, also known by its chemical name talazoparib, is a type of PARP inhibitor. It is prescribed for the treatment of HER2-negative breast cancer that is locally advanced or has spread to other parts of the body, and is associated with a BRCA1 or BRCA2 mutation. Talzenna works by disrupting the ability of cancer cells with these mutations to repair DNA damage.

Drug: Olaparib (Lynparza)
Half Life: 11.9 hours

Drug: Elahere (mirvetuximab soravtansine)
Half Life: 115.2 hours

Drug: Carboplatin (Carboplatin Novaplus)
Half Life: 120 hours

LYNPARZA is a prescribed medication that is utilized to treat advanced ovarian cancer, fallopian tube cancer, or primary peritoneal cancer in adults who possess a specific type of inherited (germline) or acquired (somatic) abnormal BRCA gene.

No, LYNPARZA is not a form of chemotherapy.

PARP mutations can potentially lead to resistance to PARP inhibitors as these inhibitors specifically target PARP proteins. Any changes or depletion in the PARP protein can impact the effectiveness of PARP inhibitors in treating the condition.